Sir,

Coronavirus disease 2019 (COVID-19) pandemic is associated with a high mortality, especially in those with severe pneumonia. Patients with COVID requiring intensive care unit (ICU) admission have higher cytokine levels compared to those who do not need ICU care.\[[@ref1]\] Even among patients admitted to ICU, those discharged from hospital had lower cytokine levels compared to those who died.\[[@ref2]\] An immunomodulator may thus be of potential benefit in managing these critically ill COVID patients. The Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R) and the World Health Organization have identified adjuvant therapy as one of the key areas of research to save lives of patients infected with COVID-19.\[[@ref3]\] A heat-killed *Mycobacterium* w (Mw), originally developed as an immunomodulator for leprosy, which acts through the toll-like receptors (TLRs) pathway and enhances the host-T cell responses.\[[@ref4]\] We have previously shown the benefit of Mw in patients with severe sepsis.\[[@ref5]\] Herein, we describe the safety of Mw in four cases of severe COVID treated with this immunomodulator \[[Table 1](#T1){ref-type="table"}\].

###### 

Details of patients who received Mycobacterium w vaccine along with standard medical care

  Days in hospital                    Patient 1   Patient 2   Patient 3                         Patient 4                                                                                                                                                                     
  ----------------------------------- ----------- ----------- --------------------------------- ----------- -------- -------- ------ -------- -------- -------- -------- -------- ------ ------ ------ --------------------------------- -------- ------ ------ ------ ------ ------
  Hemoglobin (g/dL)                   13.6        13.2        12.4                              12          11.6     11.6     11.8   12.7     12.8     13       13.3     14.5     14.8   12.4   11.8   11.3                              10.9     13.3   12.9   13.3   13.4   13
  TLC (cells/µL)                      15,200      14,800      13,800                            14,900      12,900   12,600   8500   14,000   11,500   11,700   12,400   10,700   8600   7000   7500   8900                              10,000   6400   4300   6400   5600   4300
  Neutrophils (%)                     96.6        94.1        95.5                              94.9        91.4     91.9     76     90       87.4     80.2     78       79       74     80.6   82.7   82                                82       84     80     84.9   81     66
  Lymphocytes (%)                     2.6         3.7         3.5                               3.1         4.3      4.3      13     4        6.2      7.1      7.6      9.7      12     14.6   11.7   14                                10.8     10     13.7   10.1   13     24
  Eosinophils (%)                     0.4         0.3         0.2                               0           2.2      1.6      3.2    0.1      1.2      4.7      6.4      5.3      5      0.3    0.9    1.4                               2.7      4      0.7    0.7    1.6    2
  Platelet count, cells/µL (×10^9^)   510         507         513                               528         507      513      532    243      289      381      411      454      537    112    299    247                               348      495    189    204    221    289
  CRP (mg/L)                          251         254         277                               176         127      103      29     244               108      77       17.4     10.9   100    176    155                               107      18     32     52     55     33
  Procalcitonin (ng/mL)               0.02        0.03        \-                                \-          \-       \-       0.01   0.09     0.07     0.2      \-       \-       0.04   0.08   0.08   \-                                \-       \-     \-     0.03   \-     0.03
  FiO~2~                              0.6 (RBM)   0.5         0.3                               0.28        0.24     0.24     0.21   0.36     0.36     0.28     0.24     0.21     0.21   0.5    0.4    0.28                                       0.21   0.28   0.24   0.24   0.21
  SpO~2~                              89          94          94                                94          95       98       98     93       94       96       94       94       93     85     94     94                                94       95     94     94     97     98
  PaO~2~:FiO~2~ ratio                 170         200         250                               250         280      300      300    220      280      290      300      330      273    200    220    221                               250      300    221    250    263    300
  RR                                  40          35          35                                35          30       20       18     35       30       22       20       19       25     35     25     20                                20       20     32     25     25     20
  D-dimer                             3619        1799        1795                              2033        1586     \-       1081   428      422      333      309      690      710    289    249    317                               339      126    127    172    550    590
  CKMB                                35          65          47                                                                     71                                                  44                                                              50                   
  AST (U/L)                           207         225         92                                110         111      71       76     32       28       27       24       29              36     34     34                                43       51     57     43     49     49
  ALT (U/L)                           236         259         156                               156         156      131      125    32       39       34       32       39              26     30     30                                36       69     88     54     55     56
  SAP (U/L)                           97          102         86                                100         123      122      115    114      107      96       86       83              82     89     105                               125      147    130    43     39     40
  S. cr (mg/dL)                       1.1         1.2                                           0.7         0.7      0.7      0.7    0.8      0.7      0.8      0.8      0.8             0.5    0.5    0.5                               0.4      0.4    1.2    0.8    0.9    0.9
  Albumin (g/dL)                      3.2         3.1         2.6                               2.6         2.6      2.7      2.7    3.2      3.1      3        2.9      3.22            3.4    3.4    3.3                               3        3.3    4      3.8    3.6    3.4
  Adverse event due to Mw                                     Mild erythema at injection site                                        None                                                              Mild erythema at injection site                                 None   

ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, CKMB: Creatine kinase--myocardial band, RBM: rebreathing mask, RR: Respiratory rate, SAP: Serum alkaline phosphatase, S. cr: Serum creatinine, SPO~2~: Peripheral capillary oxygen saturation by pulse oximeter, FiO~2~: Fraction of oxygen in inspired air, PaO~2~: Partial pressure of oxygen in arterial blood, TLC: Total leukocyte count, *Mw: Mycobacterium* w, CRP: C-reactive protein

All the four patients presented with a history of fever, myalgia, and dyspnea and had a history of contact with a patient of COVID-19. At presentation, patients had tachypnea \[[Table 1](#T1){ref-type="table"}\] and were hypoxemic at room air. Complete blood count showed neutrophil predominant leukocytosis and lymphocytopenia \[[Table 1](#T1){ref-type="table"}\]. The serum D-dimer levels were elevated in all patients at presentation and were \>500 ng/mL in one patient. C-reactive protein (CRP) levels were also elevated in all patients, suggesting a hyperinflammatory state. Creatine kinase--myocardial band was elevated in all patients; however, transthoracic echocardiography did not reveal any abnormality. As per our institutional protocol, all patients received standard medical care comprising oral paracetamol (for fever), oral proton-pump inhibitor for stress ulcer prophylaxis (pantoprazole 40 mg/day), and low-molecular-weight heparin for deep venous thrombosis prophylaxis (enoxaparin 1 mg/kg, once daily). Therapeutic anticoagulation (enoxaparin 1 mg/kg, twice daily) was given in patients who had D-dimer levels \>500 ng/mL. We used antibiotics (azithromycin or ceftriaxone) if patients had a total leukocyte count of \>11,000 cell/μL, procalcitonin \>0.5 ng/mL, or if they had hypotension (mean arterial blood pressure \<65 mmHg). We did not use hydroxychloroquine in any of these patients. We also used intradermal Mw (0.3 mL/day \[0.1 mL contains 0.5 × 10^(9)^ heat-killed Mw\] for 3 consecutive days, Immuvac, Cadila Pharmaceuticals, Ahmedabad, India) in addition to standard medical care.

The treatment protocol resulted in clinical and radiological improvement in all the cases \[[Figure 1](#F1){ref-type="fig"}\]. The CRP levels improved gradually \[[Figure 2](#F2){ref-type="fig"}\], and all the patients could be successfully managed without the need for mechanical ventilation. Importantly, Mw did not cause any adverse events, similar to our previous experience in patients with severe sepsis.\[[@ref5]\]

![Chest radiograph anteroposterior view of one of our patients demonstrating consolidation and infiltrates in the left upper zone at baseline (a) that improved at day 7 of admission to hospital (b)](LI-37-279-g001){#F1}

![Trend of C-reactive protein during hospital stay](LI-37-279-g002){#F2}

Based on our preliminary experience, we believe that adjunctive Mw is safe in patients with severe COVID-19 infection. However, the efficacy needs to be evaluated in a future randomized controlled trial (clinicaltrials.gov: NCT04347174).
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